HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies.
As an enterprise at the forefront of drug research, HitGen aspires to advance innovative drug discovery for the healthcare industry. We are committed to original innovation of drug discovery, continuously delivering new molecular entities to the industry, and contributing to improved human health. In 2024, while continuing to enhance our competitiveness in biopharmaceutical R&D services, we systematically integrated sustainability concepts throughout our operational processes, striving to achieve synergistic development in governance efficiency, low-carbon transmission, talent development, and community well-being.
川公网安备 51012202000492号
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information
